1800-272-662
Shopping Cart 0
countryflagAU
Login

MGC Pharmaceuticals Ltd

Healthcare US MGCLF

NoneUSD
-(-%)

Last update at 2024-09-11T10:46:45.026274Z

Day Range

--
LowHigh

52 Week Range

0.00061.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap12.30M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.69493M
  • Revenue TTM3.39M
  • Revenue Per Share TTM1.15
  • Gross Profit TTM 1.29M
  • Diluted EPS TTM-4.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -21.13152M -17.13873M -13.53175M -18.81432M -1.87636M
Minority interest 0.31M 0.37M -0.00865M -0.01097M -0.16116M
Net income -20.82358M -16.76576M -13.96511M -19.36309M -2.30933M
Selling general administrative 13.42M 8.28M 5.73M 6.61M 2.61M
Selling and marketing expenses - 0.95M 0.58M 0.56M 0.57M
Gross profit 1.45M 1.63M 1.31M 0.13M 0.30M
Reconciled depreciation 0.49M 0.50M 0.49M 0.48M 0.26M
Ebit -15.23443M -14.62628M -12.48741M -9.49769M 0.62M
Ebitda -20.30077M -14.12199M -11.99600M -9.01656M 0.88M
Depreciation and amortization - 0.50M 0.49M 0.48M 0.26M
Non operating income net other - - - - 0.00000M
Operating income -15.69725M -14.62628M -12.48741M -9.49769M 0.62M
Other operating expenses 1.73M 18.10M 15.03M 14.45M 9.70M
Interest expense 0.34M 0.19M 0.37M 0.14M 0.00800M
Tax provision 0.00202M 0.00000M -0.02728M 0.00000M 0.03M
Interest income 0.00024M 0.00030M 0.00763M 0.01M 0.20M
Net interest income -0.33701M -0.18975M -0.36150M -0.12325M 0.19M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.00202M -1.35950M -0.02728M 1.21M 0.03M
Total revenue 3.39M 4.65M 2.96M 2.03M 0.66M
Total operating expenses - 15.08M 13.38M 12.55M 9.34M
Cost of revenue 1.94M 3.01M 1.65M 1.90M 0.36M
Total other income expense net -5.09725M -3.49897M -1.10033M -8.65673M 6.97M
Discontinued operations - - -0.46264M -0.60043M 2.43M
Net income from continuing ops -21.13353M -17.13873M -13.50447M -18.76980M -1.90367M
Net income applicable to common shares -20.82358M -20.34744M -15.86998M -19.36309M -8.57933M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 9.88M 18.56M 24.24M 7.93M 13.00M
Intangible assets - - - - 5.03M
Earning assets - - - - -
Other current assets - -0.90063M 0.83M 0.55M 0.09M
Total liab 18.02M 13.38M 10.41M 4.83M 2.20M
Total stockholder equity -7.50606M 5.74M 13.83M 3.11M 10.96M
Deferred long term liab - - - - 0.00000M
Other current liab 1.24M 3.67M 0.00798M 0.11M 0.43M
Common stock 103.69M 97.44M 77.75M 60.15M 49.13M
Capital stock 103.71M 97.44M 84.51M 60.15M 49.13M
Retained earnings -119.16892M -94.76365M -76.09302M -62.12792M -41.46483M
Other liab 4.30M 3.70M 2.51M 0.02M 0.02M
Good will - 5.38M 7.05M - 0.00000M
Other assets - 0.16M 0.56M - 0.00000M
Cash 0.24M 1.79M 5.43M 1.87M 2.35M
Cash and equivalents - - - - -
Total current liabilities 13.33M 7.71M 6.13M 2.97M 2.18M
Current deferred revenue - 1.38M -4.28168M 0.10M 0.59M
Net debt - 0.51M 1.24M 0.03M -2.35409M
Short term debt - 0.15M 4.90M 0.05M 0.00000M
Short long term debt - 2.10M 4.69M - 0.00000M
Short long term debt total - 2.29M 6.67M 1.90M -
Other stockholder equity 8.08M -5.87619M 4.86M 5.08M 4.59M
Property plant equipment 7.45M 8.80M 7.14M 4.02M 1.47M
Total current assets 2.53M 6.46M 9.48M 3.23M 3.72M
Long term investments - 0.16M - 0.67M 2.77M
Net tangible assets -7.40308M 2.69M 6.79M 3.11M 5.93M
Short term investments - - - - 0.00000M
Net receivables 0.53M 3.35M 2.35M 0.41M 1.14M
Long term debt - - - - 0.00000M
Inventory 1.36M 2.22M 0.87M 0.40M 0.14M
Accounts payable 2.19M 2.50M 1.22M 2.71M 1.16M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - 8.94M 7.32M 5.08M 3.29M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - -3.14208M 0.56M 0.67M 2.77M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 7.45M 12.10M 14.75M 4.70M 9.28M
Capital lease obligations 0.58M 2.29M 1.98M 1.90M 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.05M -0.15597M 0.30M 0.00547M 0.00547M
Change to liabilities 0.19M 1.63M -0.81997M 0.94M 0.63M
Total cashflows from investing activities 0.61M -1.11118M -1.49378M -0.96988M -0.94703M
Net borrowings 6.96M -0.20158M 5.49M -0.18361M -0.18361M
Total cash from financing activities 9.73M 9.74M 16.68M 10.65M 0.03M
Change to operating activities - - - - 0.00000M
Net income -20.82358M -20.34744M -15.86998M -19.36309M -8.57933M
Change in cash -1.64653M -3.66475M 3.56M -0.48071M -7.50489M
Begin period cash flow 1.89M 5.43M 1.87M 2.35M 9.86M
End period cash flow 0.24M 1.77M 5.43M 1.87M 2.35M
Total cash from operating activities -11.98517M -12.15822M -11.98961M -9.95687M -6.35421M
Issuance of capital stock 2.70M 10.76M 12.76M 11.43M 0.04M
Depreciation 0.75M 0.14M 0.49M 0.48M 0.26M
Other cashflows from investing activities 0.80M 1.59M 2.45M 2.45M 2.45M
Dividends paid - -0.06142M - - 0.00000M
Change to inventory 0.48M -0.96536M -0.47021M -0.26344M 0.57M
Change to account receivables 1.41M 1.29M -2.22031M 0.27M -0.29497M
Sale purchase of stock -0.08143M -0.76406M -1.20265M -0.78768M -0.00895M
Other cashflows from financing activities -0.31784M -0.32443M 5.12M -0.96988M -0.94703M
Change to netincome 6.02M 6.09M 6.90M 7.98M 1.05M
Capital expenditures 0.19M 4.02M 3.33M 0.96M 0.36M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -11.25952M -4.01786M -3.32710M -0.96210M -0.36215M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MGCLF
MGC Pharmaceuticals Ltd		 - -% - - 15.20 3.46 5.69 3.42 -0.5766
ZTS
Zoetis Inc		 0.16 0.14% 115.62 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.51 2.02% 24.74 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 124.91 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 - -% 17.77 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

MGC Pharmaceuticals Ltd

1202 Hay Street, West Perth, WA, Australia, 6005

Key Executives

Name Title Year Born
Mr. Roby Reuven Zomer Co-Founder, CEO, MD & Exec. Director 1980
Ms. Angela-Marie Graham Group Chief Financial Officer NA
Ms. Yifat Steuer Deputy CEO & COO NA
Mr. Amir Polak Chief Technology Officer NA
Ms. Nicole Ann Godresse Global Chief Sales Officer NA
Ms. Sabina Suljakovic Head of the Quality Assurance Department NA
Dr. Nadya Lisovoder Chief Medical Officer NA
Ms. Sasha Friedman Deputy CEO NA
Yair Tal Chief Information Security Officer NA
Mr. Robert Clements Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.